Acer therapeutics and relief therapeutics announce presentation of acer-001 data at the society for inherited metabolic disorders annual meeting

Newton, ma and geneva, switzerland / accesswire / april 12, 2022 / acer therapeutics inc. (nasdaq:acer) ("acer") and its collaboration partner, relief therapeutics holding sa (six:rlf)(otcqb:rlftf)(otcqb:rlfty) ("relief"), today announced the presentation of data evaluating the bioavailability, bioequivalence and taste attributes of taste-masked sodium phenylbutyrate (acer-001) compared to sodium phenylbutyrate (buphenyl(r)) powder during poster sessions at the recent society for inherited metabolic disorders (simd) annual meeting on april 10-13, 2022 in orlando, florida. "these data further support our belief that, if approved, acer-001 could offer an alternative to current therapies that may lead to meaningful clinical outcomes in ucds patients," said adrian quartel, md, cmo of acer.
ACER Ratings Summary
ACER Quant Ranking